Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Conatus Pharmaceuticals Inc (NASDAQ:CNAT)

4.95
Delayed Data
As of Feb 24
 +0.13 / +2.70%
Today’s Change
1.45
Today|||52-Week Range
6.30
-6.07%
Year-to-Date
LME Hands Gold Banks License to Print Money
Feb 23 / Investing Channel - Paid Partner Content
 

Today’s Trading

Previous close4.82
Today’s open4.80
Day’s range4.75 - 4.96
Volume134,132
Average volume (3 months)1,367,484
Market cap$129.0M
Dividend yield--
Data as of 02/24/2017

Growth & Valuation

Earnings growth (last year)+9.72%
Earnings growth (this year)+1.28%
Earnings growth (next 5 years)+74.00%
Revenue growth (last year)--
P/E ratioNM
Price/Sales--
Price/Book2.84

Competitors

 Today’s
change
Today’s
% change
MDWDMediwound Ltd-0.15-2.50%
AGTCApplied Genetic Tech...-0.15-2.03%
PPHMPeregrine Pharmaceut...+0.01+1.24%
NEOSNeos Therapeutics In...+0.25+4.39%
Data as of 4:00pm ET, 02/24/2017

Financials

Next reporting dateMarch 15, 2017
EPS forecast (this quarter)-$0.32
Annual revenue (last year)$0.00
Annual profit (last year)-$24.1M
Net profit margin--

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Steven J. Mento
Chief Financial Officer, Secretary &
SVP-Finance
Charles J. Cashion
Corporate headquarters
San Diego, California

Forecasts


Search for Jobs